<DOC>
	<DOCNO>NCT02068027</DOCNO>
	<brief_summary>The purpose study determine whether clonidine gel effective treatment reduce pain associate painful diabetic neuropathy .</brief_summary>
	<brief_title>Safety Efficacy Study Clonidine Hydrochloride Topical Gel , 0.1 % Treatment Pain Associated With Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>The subject provide write informed consent . The subject outpatient age 18 85 year ( inclusive ) time Screening Visit . The subject Type 1 Type 2 diabetes mellitus glycemic control optimize stable diet therapy , oral antihyperglycemic agent and/or insulin , least three ( 3 ) month prior Screening Visit . The subject must male nonpregnant , nonlactating female . Females must practice acceptable method birth control , surgically sterile postmenopausal ( amenorrhea ≥12 month ) . Nonpregnancy confirm ( applicable ) pregnancy test conduct Screening Randomization Visits . Doublebarrier method , hormonal contraceptive , abstinence acceptable birth control method study . The subject chronic pain attributable symmetrical stock distribution neuropathy low extremity least three ( 3 ) month . A loss distal sensation and/or tingle paresthesia primarily toe finger acceptable , must secondary importance distal neuropathic pain . Pain clearly localized area neuropathy ( foot ) subject able distinguish pain ( target pain ) painful area condition . The subject average pain score relevant target pain foot ≥4 11point Numeric Pain Rating Scale previous 24 hour Screening . The subject pain score least 2 , 11point Numeric Pain Rating Scale , within 30 minute follow topical 0.1 % capsaicin application occlusive dress pretibial area . The subject mean daily average pain score relevant target pain foot ≥4 11point Numeric Pain Rating Scale Baseline Phase . The subject met pain evaluation score criterion end Placebo Leadin Phase mean daily average pain score relevant target pain foot ≥4 11point Numeric Pain Rating Scale without decrease pain score great 20 % compare Baseline Phase score 11point Numeric Pain Rating Scale . The subject medically stable least 30 day prior Screening Visit , opinion Investigator , otherwise good general health base medical history , physical examination , ECG , laboratory evaluation . If take chronic oral pain medication , subject must stable regimen least 14 day prior Baseline Visit expectation medication , dose ( ) schedule remain stable throughout study . For medication contain nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin , subject must stable dose least 7 day prior Baseline Visit . As needed pain medication limit acetaminophen Day 8 end treatment period . Low dose aspirin ( 81 mg/day ) consider analgesic therapy . Subject compliant daily pain assessment Baseline Phase Placebo Lead Phase study record Numeric Pain Rating Scale score least 5 day last 3 day previous 7 day . Subject alert capability apply topical gel foot three time daily . A caregiver , train study staff apply study drug , would suitable alternative selfapplication treatment . The subject neuropathy secondary nondiabetic cause opinion Investigator ( e.g. , significant vasculitis , collagen vascular disorder , familial neuropathy , alcoholism , pernicious anemia , hepatitis , malignancy , syphilis , postherpetic neuralgia , chronic inflammatory demyelinate polyradiculopathy , human immunodeficiency virus [ HIV ] , medicationinduced neuropathy , vitamin B12 deficiency ) . The subject significant neurological disorder condition cause symptom mimic peripheral neuropathy might confound assessment painful diabetic neuropathy ( e.g. , stroke distal neurological deficit , mononeuritis multiplex , lumbar radiculopathy , multiple sclerosis ) significant asymmetric neuropathic sign symptom . The subject sustain pain intensity great bilateral neuropathic pain feet/toes . The subject use implanted medical device ( e.g. , spinal cord stimulator , intrathecal pump , peripheral nerve stimulator ) treatment pain . The subject pinprick sensitivity Neuropen test noncalloused area foot . The subject clinically hypotensive rest diastolic blood pressure &lt; 60 mm Hg systolic blood pressure &lt; 90 mm Hg . The subject recent history ( within past 3 month ) current symptom orthostatic hypotension sudden fall blood pressure stand accompanied dizziness lightheadedness . The subject history foot toe amputation , active foot toe ulcer . The subject significant unstable medical psychiatric condition , opinion Investigator , would interfere his/her ability participate study . The subject history substance abuse disorder define Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) within past year , current evidence substance abuse disorder , receive medicinal treatment drug abuse , test positive upon urine drug screen nonprescribed substance abuse . The subject use capsaicin foot great 2 consecutive week previous 3 month . The subject symptomatic severe coronary insufficiency , clinically significant cardiac conduction disturbance , myocardial infarction ( within last 12 month ) , moderate severe cerebrovascular disease , severe chronic obstructive pulmonary disease ( COPD ) require oxygen therapy . The subject serum creatinine value &gt; 2.0 mg/dL value alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.5 time upper limit normal Screening . The subject dose investigational drug within 30 day prior Screening Visit . The subject likely noncompliant unreliable provide pain rating judge Investigator . The subject evidence clinically significant peripheral vascular disease evidence history intermittent claudication evidence vascular ulcer , include venous stasis ulcer . The subject prior treatment clonidine topical gel . The subject currently take take clonidine form ( oral , transdermal patch ) past 4 week . The subject know hypersensitivity intolerance clonidine . Except acetaminophen , subject currently receive medication could affect neuropathic pain stable dose least 14 day prior Baseline Visit ( medication contain NSAIDs aspirin must stable 7 day prior Baseline Visit ) . The subject receive nonoral pain medication ( ) ( transdermal , topical , subcutaneous , intramuscular , intravenous , intrarectal , sublingual , transmucosal ) and/or use `` alternative medicine '' product technique ( acupuncture , naturopathy , homeopathy , etc . ) pain treatment ≤7 day prior Baseline Visit . Subject history malignancy within past 5 year exception successfully treat nonmetastatic basal cell squamous cell carcinoma skin and/or localize carcinoma situ cervix . The subject hospitalize within 30 day Screening Visit , plan surgery study period . The subject clinical evidence pedal edema venous stasis disease associate significant skin change physical examination . The subject clinically relevant painful foot condition , tarsal tunnel syndrome , plantar fasciitis , Morton 's neuroma , painful bunion , arthritis foot/ankle , condition may associate numbness foot . The subject dermatologic condition low extremity could affect study drug absorption ( e.g. , severe edema ) . The subject current symptom depression Beck Depression Inventory II score &gt; 19 Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Pain</keyword>
	<keyword>Foot pain</keyword>
	<keyword>Neuropathy</keyword>
</DOC>